Literature DB >> 22021194

Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway.

Elaine R Nimmo1, James G Prendergast, Marian C Aldhous, Nicholas A Kennedy, Paul Henderson, Hazel E Drummond, Bernard H Ramsahoye, David C Wilson, Colin A Semple, Jack Satsangi.   

Abstract

BACKGROUND: Germline variation in the 71 Crohn's disease (CD) loci implicated by genome-wide association studies (GWAS) only accounts for approximately 25% of estimated heritability. The contribution of epigenetic alterations to disease pathogenesis is emerging as a research priority.
MATERIALS AND METHODS: The methylation status of 27,578 CpG sites across the genome was analyzed using the Illumina Human Methylation27 assay in DNA extracted from whole blood samples from 40 adult females (21 ileal CD, 19 healthy controls) and 16 girls with childhood-onset CD, all nonsmokers. Our primary analysis compared methylation profiles in adult cases and controls.
RESULTS: Our data define a global methylation profile characteristic of ileal CD. In all, 1117 sites were differentially methylated (corrected P < 0.01); 50 showed significantly altered methylation in cases compared with controls (uncorrected P < 10(-6), corrected P < 0.0006), including genes altering immune activation: MAPK13, FASLG, PRF1, S100A13, RIPK3, and IL-21R. Gene ontology analyses implicated immunity-related pathways as targets of epigenetic modification (immune system processes [P = 1.3 × 10(-22)], immune response [P = 8.1 × 10(-16)], defense responses to bacteria [P = 1.8 × 10(-15)]). Ingenuity canonical pathway analyses implicated dendritic cell activity (P = 2.4 × 10(-8)) and differential regulation of cytokines by interleukin (IL)-17A and IL-17F (P = 5.8 × 10(-7)). We identified a significant enrichment of methylation changes within 50 kb of CD GWAS loci (8.6-fold [P = 0.021] in adults; 2.4-fold [P = 0.009] in adults and children combined), including IL-27, IL-19, TNF, MST1, and NOD2. Methylation status was predictive of disease status (sensitivity 0.71, specificity 0.83). Disease activity, drug therapy, NOD2 and DNMT3A genotypes were not associated with methylation changes.
CONCLUSIONS: These data provide an important insight into the impact of epigenetic mechanisms in the pathogenesis of CD.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021194     DOI: 10.1002/ibd.21912

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  69 in total

1.  DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.

Authors:  Edel McDermott; Elizabeth J Ryan; Miriam Tosetto; David Gibson; Joe Burrage; Denise Keegan; Kathryn Byrne; Eimear Crowe; Gillian Sexton; Kevin Malone; R Alan Harris; Richard Kellermayer; Jonathan Mill; Garret Cullen; Glen A Doherty; Hugh Mulcahy; Therese M Murphy
Journal:  J Crohns Colitis       Date:  2015-09-28       Impact factor: 9.071

Review 2.  Epigenetic alterations in inflammatory bowel disease and cancer.

Authors:  Joo Mi Yi; Tae Oh Kim
Journal:  Intest Res       Date:  2015-04-27

3.  Blood-Derived DNA Methylation Signatures of Crohn's Disease and Severity of Intestinal Inflammation.

Authors:  Hari K Somineni; Suresh Venkateswaran; Varun Kilaru; Urko M Marigorta; Angela Mo; David T Okou; Richard Kellermayer; Kajari Mondal; Dawayland Cobb; Thomas D Walters; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Joel R Rosh; David R Mack; Melvin B Heyman; Susan S Baker; Michael C Stephens; Robert N Baldassano; James F Markowitz; Marla C Dubinsky; Judy Cho; Jeffrey S Hyams; Lee A Denson; Greg Gibson; David J Cutler; Karen N Conneely; Alicia K Smith; Subra Kugathasan
Journal:  Gastroenterology       Date:  2019-02-16       Impact factor: 22.682

4.  Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity.

Authors:  T W Kragstrup; T Andersen; C Holm; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 5.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

6.  Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort.

Authors:  Ashwin N Ananthakrishnan; Hailiang Huang; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ramnik J Xavier
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

Review 7.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.

Authors:  Heitor S P de Souza; Claudio Fiocchi; Dimitrios Iliopoulos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

8.  Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity.

Authors:  J E Aguirre; J H Winston; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2017-04-25       Impact factor: 3.598

Review 9.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 10.  Epigenetics and the developmental origins of inflammatory bowel diseases.

Authors:  Richard Kellermayer
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.